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1. ABSTRACT 
Mitochondria contain their own extra-nuclear genome in the form of mitochondrial DNA (MtDNA), a 
small circular DNA molecule which is present as multiple copies within cells. MtDNA levels can change in 
response to physiological conditions and oxidative stress, and MtDNA copy numbers relative to nuclear 
genome copy numbers have been proposed as a biomarker of mitochondrial dysfunction. In the last 
decade, increasing number of studies have reported alterations in MtDNA in body fluids and tissues 
from human populations in both common diseases and in response to drug/environmental toxicity. 
Changes in MtDNA levels have been reported in prevalent diseases such as diabetes and its 
complications, cancer, HIV, neurodegenerative diseases, cardiovascular disease, and also correlate with 
patient response to chemotherapy, anticancer drugs and HIV treatment. Additionally, cell free MtDNA 
has emerged as a potential danger associated molecular pattern (DAMP) molecule with the potential to 
induce inflammation, and has been linked to increased risk of cardiovascular disease, sepsis and 
mortality in intensive care unit patients. However, although drug-induced mitochondrial dysfunction is 
accepted as a key issue to resolve in order to prevent drug toxicity, few studies have used MtDNA as a 
potential indicator of drug toxicity during drug design and development. Furthermore, methodological 
issues in accurately measuring MtDNA have resulted in conflicting data for the same disease in different 
populations, and physiological levels of MtDNA in human and animal model body fluids, tissues and 
organs remain to be determined . The accurate measurement of MtDNA requires careful assay design, 
avoidance of co-amplification of nuclear pseudogenes, and clarification of whether cellular and cell free 
MtDNA is being measured, and there is a clear need for the improvement of methodology. However 
despite these issues, we suggest that that the determination of the impact of drugs on cellular and cell 
free MtDNA could provide an extremely useful indicator of drug induced toxicity, and could lead to its 
utilisation in parallel with existing methodologies in the initial drug development and testing phase as 
well as in follow up clinical trials to test drug efficacy and patient response.   
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2. INTRODUCTION 
Mitochondria are double membrane organelles which produce the majority of cellular energy in 
eukaryotes in the form of adenosine triphosphate (ATP) through oxidative phosphorylation (OXPHOS). 
As well as energy production, mitochondria have many other crucial cellular functions, including the 
regulation of intracellular calcium homeostasis and apoptosis (Wojtczak and Zablocki, 2008).  Because of 
their role in energy production and other key cellular functions, damage to mitochondria can have a 
serious impact on the health of cells and tissues and can result in a variety of diseases (Wallace, 1999). 
In recent years it has become widely accepted that systemic damage to mitochondria, often termed 
acquired mitochondrial dysfunction, is involved in many common human diseases (Michel et al., 2012, 
Wallace, 1999, Malik et al., 2013) as well as in drug induced toxicity (Dykens and Will, 2008) leading to a 
growing interest in developing biomarkers of mitochondrial health.  
Mitochondrial energy production is carried out within the double membrane of mitochondria via 
electron transport through a complex of proteins known as the electron transport chain. During 
mitochondrial ATP synthesis, electron leakage from the electron transport chain can lead to the 
production of reactive oxygen species (ROS), which in normal conditions is involved in signalling, 
however excess ROS can lead to oxidative stress.  In normal healthy cells mitochondria are present as an 
interconnected network or several networks rather than the old fashioned view of solitary organelles 
(Bereiter-Hahn et al., 2008). Cellular mitochondrial content is regulated via mitochondrial biogenesis 
and degradation of mitochondria via mitophagy. The mitochondrial mass reflects the bioenergetics 
requirements of the host cell, and can vary from tens to thousands of mitochondria per cell. The number 
of mitochondria in different cell types therefore varies widely, for example a brain cell may have around 
2000 mitochondria (Uranova et al., 2001),  a white blood cell may have less than a hundred (Selak et al., 
2011) and oocytes may contain several hundred thousand mitochondria (Duran et al, 2011, Piko and 
Matsumoto, 1976).  The number of mitochondria in a particular cell type also can vary in response to 
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environmental and physiological factors, for example cellular redox balance or signalling pathways 
(Michel et al., 2012, Rodriguez-Enriquez et al., 2009). Damage to mitochondria, once it exceeds a 
threshold, can affect a range of important cellular functions and can contribute to the development of a 
large number of diseases (Michel et al., 2012; Wallace, 1999). Cells and tissues with high bio-energetic 
needs and consequently high mitochondrial mass are particularly sensitive to the impact of 
mitochondrial damage.  Consequently, there is a strong need for translational biomarkers which can be 
used for early detection of potential mitochondrial dysfunction before irreversible damage to 
susceptible cells, tissues and organs takes place (Figure 1).  
Mitochondria are the only cytosolic organelles in eukaryotes that contain endogenous DNA outside of 
the nucleus. Mitochondrial DNA (MtDNA) is normally located within mitochondria as a small, circular, 
extra-nuclear genome. Each mitochondrion can contain multiple copies of MtDNA (Bogenhagen, 2011, 
Falkenberg et al., 2007), and since cells contain many mitochondria, MtDNA is present as multiple copies 
within cells. The amount of cellular MtDNA has been shown to correlate with mitochondrial function 
and OXPHOS activity (Hock and Kralli, 2009, Williams, 1986) and this has led to studies using its quantity 
as a determinant of mitochondrial activity.  
In the last decade, numerous studies have shown that MtDNA levels are altered in disease conditions in 
tissues and in circulation, and additionally MtDNA has emerged as a danger associated molecular 
pattern (DAMP) with the potential to induce inflammation (Zhang et al., 2010). However, to date, few 
studies have attempted to use alterations in cellular or cell-free MtDNA in studies of drug toxicity. In this 
chapter, I propose the potential of using MtDNA levels in drug toxicity studies, both in–vitro and animal 
studies, as well as in clinical studies, to monitor the effects of pharmacological compounds on 
mitochondrial health.  
3. THE MITOCHONDRIAL GENOME.  
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The human mitochondrial genome is 16,569bp long, contains 37 genes, encoding 13 proteins and 24 
transfer RNA and ribosomal RNAs crucial to mitochondrial function. The remaining mitochondrial 
proteins which are required to make functional mitochondria are coded for and transcribed from the 
nuclear genome, with resultant transcripts being  translated into proteins at cytosolic ribosomes and 
transported into mitochondria for assembly (Scheffler, 2008).  Mitochondria contain >1000 different 
proteins, some of which show tissue specific profiles (Johnson et al., 2007, Smith et al., 2012).  The 
correct functioning of all 37 genes encoded by the mitochondrial genome is crucial but to make 
functional mitochondria and a functional electron transport chain. This is because MtDNA encodes 13 
protein subunits crucial for the mitochondrial OXPHOS machinery as well as various RNAs required for 
mitochondrial protein synthesis. These components, together with nuclear encoded proteins, result in 
the assembly of functional mitochondrial mass in cells and allow mitochondrial function and energy 
production in the form of ATP. Therefore, MtDNA has a crucial role in cells by acting as a template for 
both transcription and replication to generate functional mitochondria. Bio-energetically active tissues 
such as brain, heart, kidney and muscle with a high mitochondrial content thereby can contain hundreds 
of thousands of copies of MtDNA per cell, whereas other tissues and cells such as blood cells with less 
mitochondrial mass contain considerably less MtDNA per cell (Mercer et al., 2011, Fernandez-Vizarra et 
al., 2011, Malik et al., 2016).  
Under normal conditions, the amount of MtDNA can change in response to cellular physiological signals, 
with cells maintaining a balance between MtDNA replication and transcription to allow mitochondrial 
biogenesis as needed. However, in certain disease conditions, this relationship breaks down and cellular 
MtDNA content may increase in response to oxidative stress but transcription and translation of MtDNA 
are blocked, leading to increased cellular MtDNA which in time may become damaged. MtDNA damage 
could comprise of mutations, deletions and oxidation. The integrity and amount of MtDNA present in 
cells can impact on mitochondrial function (Madsen-Bouterse et al., 2010, Czajka et al., 2015). MtDNA 
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damage can have downstream effects on cellular health, causing defects in the OXPHOS machinery, 
cellular signalling, and subsequently leading to oxidative stress, an energy deficit and eventually cell 
death. MtDNA damage may thus lead to release of cellular content including MtDNA into circulation, 
and if systemic mitochondrial dysfunction is present, the release of large amounts of cellular contents 
and MtDNA may compromise the body’s capacity to clear circulating MtDNA.   
Some of the key differences between the human mitochondrial and nuclear genomes are listed in Table 
1. Eukaryotic DNA in the nuclear genome is organised as chromosomes, large double stranded linear 
molecules stored as highly packaged and compact structures and are stored as chromatin, a DNA- 
histone protein complex. In contrast, MtDNA exists as a small circular double stranded DNA molecule 
organised into a nucleoprotein with the transcription factor A (TFAM) protein, and termed a nucleoid. 
Nucleoids are found associated with the inner mitochondrial membrane (Bogenhagen, 2011, Falkenberg 
et al., 2007) and individual mitochondria can contain several copies of the mitochondrial genome 
(Navratil et al., 2007; Veltri et al., 1990). The differences between the mitochondrial and nuclear 
genome (table 1) can significantly impact on methodology used for the measurement of MtDNA, and are 
discussed in more detail below (see section 5).  
4. IS MITOCHONDRIAL DNA A USEFUL BIOMARKER OF MITOCHONDRIAL DYSFUNCTION  
The amount of MtDNA in a cell could provide a major regulatory point in mitochondrial activity, as the 
transcription of mitochondrial genes is proportional to their copy number (Hock and Kralli, 2009, 
Williams, 1986). Indeed, MtDNA has been widely utilised as an indicator of cellular mitochondrial 
content. We previously proposed the hypothesis that MtDNA content measured as Mt/N (mitochondrial 
to nuclear genome ratio) is a biomarker of mitochondrial dysfunction (Figure 2, Malik and Czajka 2012).  
The premise of this theory is that the Mt/N value of a particular cell type changes in conditions of stress 
such as redox imbalance or other altered signalling. The initial response to increased cellular stress 
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would be an adaptive response where Mt/N values would increase as a result of increased 
mitochondrial biogenesis. In conditions of persistent oxidative stress, alterations in Mt/N may represent 
a mixture of intact and functional mitochondrial genomes as well as damaged MtDNA fragments which 
have not been properly removed. Oxidative stress may eventually lead to the depletion of Mt/N 
alongside mitochondrial dysfunction resulting from damaged MtDNA and proteins. Accumulation of 
damaged MtDNA in the cell may lead to an inflammatory response as MtDNA is un-methylated and 
resembles bacterial DNA (Figure 2).  
Oxidative stress is a common feature in many diseases including diabetes complications, cardiovascular 
disease, neurodegenerative disease, cancer, renal disease and others (Halliwell and Gutteridge, 2007). 
Free radicals, also known as reactive oxygen species (ROS) are produced as a side product of using 
oxygen for energy production, and are highly reactive molecules with unpaired electrons. It has been 
estimated that approximately 5% of the oxygen being used in the body turns into ROS,  as a 
consequence of electron leakage from the electron transport chain during oxidative phosphorylation  
(Adam-Vizi and Chinopoulos, 2006; Halliwell and Gutteridge, 2007; Turrens, 2003). With the exception of 
phagocytes, cells produce more than 95% of their intracellular ROS via the mitochondrial electron 
transport chain. Most cells are well equipped to deal with intracellular ROS as they have endogenous 
antioxidant systems such as glutathione peroxidise, catalase, and superoxide dismutase (Nohl, 1991; 
Nordberg and Arner, 2001).  These highly abundant cellular  proteins, present in most cells, can 
sequester ROS by accepting electrons and becoming oxidised, and are usually recycled by donating their 
electrons to chains of acceptors such as reduced nicotinamide adenine dinucleotide  phosphate 
(NADPH) (Rydstrom, 2006). The cell’s metabolic performance is closely related to its antioxidant 
response, and NADPH levels are central to the activity of many antioxidants (Kirsch and De Groot, 2001).  
Despite these endogenous antioxidant systems, when chronic ROS production occurs, the cell’s ROS 
levels can exceed their detoxification and cause a shift in the redox balance. Free radicals which escape 
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the cells’ antioxidant response can oxidise proteins, lipids and DNA molecules within the cell, leading to 
altered properties and cellular damage.  Many common drugs cause mitochondrial oxidative stress 
(reviewed by Mehta et al., 2008), and many common diseases such as diabetes and its complications, 
cancer, neurodegenerative disorders as well as ageing have been shown to have redox impairment  
(Halliwell and Gutteridge, 2007; Wallace, 1999; Ying, 2008).   
The mitochondrial life cycle controls cellular mitochondrial mass, through both mitochondrial 
biogenesis, the synthesis of new mitochondria, and mitophagy, the degradation and removal of 
damaged mitochondria. Evidence indicates that both biogenesis and mitophagy may be impaired in 
conditions of oxidative stress. Abnormal signalling results in an adaptive response through enhanced 
production of mitochondria (Michel et al., 2012). Reduced removal results in the accumulation of 
damaged mitochondria (Kim et al., 2007) as is the case for diabetes where blockage of the electron 
transport chain at complex III results in accumulation of excess ROS (Giacco and Brownlee, 2010; 
Newsholme et al., 2007).  As mitochondrial DNA is located close to the source of ROS production, the 
DNA itself can become damaged resulting in accumulation of deletions and mutations (Bohr, 2002; 
Croteau and Bohr, 1997; Indo et al., 2007).  
Accumulation of damaged MtDNA, alongside its ineffective clearance, may result in its release from 
damaged mitochondria and cells and cause a chronic innate inflammatory response. In such a scenario, 
MtDNA could contribute directly to pathology because unlike eukaryotic nuclear DNA which is often 
methylated at CpG motifs within DNA, MtDNA DNA is largely un-methylated like bacterial DNA. Un-
methylated DNA is known to cause immune responses via the intracellular Toll like receptor (TLR) 9 
(Barbalat et al., 2011; Sparwasser et al., 1997). Injection of oxidised MtDNA directly causes inflammatory 
arthritis in mice (Collins et al., 2004). Zhang et al., 2010 showed that circulating MtDNA levels were 
markedly increased in trauma patients and provided a mechanistic explanation for this observation by 
showing that MtDNA could directly activate human neutrophils via TLR 9 (Zhang et al., 2010).  
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Accumulation of MtDNA in the cytosol of cardiomyocytes resulted in heart failure in a mouse model 
where the normal process of degradation of damaged mitochondrial DNA had been disrupted (Oka et 
al., 2012). Therefore, altered MtDNA levels may elicit an increased immune response resulting in chronic 
inflammation and oxidative stress, thus contributing directly to pathogenesis. In parallel, loss of cellular 
MtDNA would cause reduced mitochondrial function and a bioenergetic deficit, which would further 
impair the cell’s ability to repair cellular damage.  
According to our hypothesis (Figure 2), in conditions of oxidative stress, the transcriptional and 
replication machinery of mitochondrial biogenesis will be up-regulated as a maladaptive response  
resulting in increased mitochondrial biogenesis via replication of the mitochondrial genome (Malik & 
Czajka, 2013) ). There are some studies in the literature supporting the view that ROS can lead to 
increased mitochondrial biogenesis. In human endothelial cells,  homocysteine-induced ROS resulted in 
increased expression of TFAM and NRF-1 genes, and this effect was abolished by antioxidant treatment 
(Perez-de-Arce et al., 2005). In human lung fibroblasts, following treatment with hydrogen peroxide to 
induce oxidative stress, there was an increase in mitochondrial mass and MtDNA copy number (Lee et 
al., 2000). Up-regulation of transcriptional machinery was shown to be protective against oxidative 
stress, for example over-expression of recombinant TFAM in-vitro and in-vivo can stimulate 
mitochondrial biogenesis and reduce oxidative stress (Thomas et al., 2011). Lee and Wei proposed that 
mild oxidative stress leads to increased mitochondrial biogenesis and copy number, and suggested that 
the stress response of cells in terms of mitochondrial copy numbers and biogenesis could be key in 
terms of the life or the death of the cell and should be further investigated (Lee and Wei, 2005). 
Moreover, in a study of 156 healthy subjects, ranging from the ages of 25 to 80, it was found that 
MtDNA content in leucocytes was higher in volunteers with increased levels of oxidative stress (Liu et 
al., 2003). 
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We recently showed that growth of primary human renal glomerular mesangial cells in high glucose led 
to a rapid increase in cellular MtDNA in parallel with increased oxidative stress (Czajka et al 2015) and 
that these changes preceded other measures of mitochondrial dysfunction. Interestingly, the increased 
MtDNA was not functional since MtDNA encoded mRNAs were not up-regulated in parallel. Instead, the 
MtDNA was damaged and there was up-regulation of the TLR9 pathway in parallel (Czajka et al., 2016). 
These data support the hypothesis that oxidative stress can lead to early and detectable changes in 
MtDNA. Interestingly, we further showed that the MtDNA changes preceded mitochondrial dysfunction, 
since MtDNA changes were detectable within 24 hours of growth in high glucose whereas cellular 
respiration remained functional until 8 days (Figure 3). This further supports the view that MtDNA 
changes take place early on and maybe used as an indicator of mitochondrial dysfunction before 
damage to cellular respiration takes place. These data also suggest that early changes in MtDNA may 
cause a cascade of pro-inflammatory responses via the early activation of the TLR9 pathway.  
5. METHODOLOGICAL ISSUES FOR MEASURING MITOCHONDRIAL DNA CONTENT  
As discussed in more detail below and previously described, disease associated changes in MtDNA 
content from various body fluids have been reported in a broad range of human diseases, as well as in 
normal development, fertility, and exposure to environmental factors (Malik and Czajka 2013). The use 
of body fluids for these studies is an attractive option as tissues and organs cannot easily be accessed, 
and most published studies have tended to use blood samples. A common method for measuring 
MtDNA content is to quantify a mitochondrial-encoded gene relative to a nuclear-encoded gene to 
determine the mitochondrial genome to nuclear genome ratio which we have termed Mt/N (Malik et 
al., 2009). Earlier studies measuring Mt/N utilised hybridization  (Rodriguez-Enriquez et al., 2009; Veltri 
et al., 1990) whereas more recent studies use real time  (Cavelier et al., 2000; D'Souza et al., 2007; Malik 
et al., 2011) or digital (Masser et al., 2016) quantitative PCR (qPCR), a highly sensitive technique which is 
fast, adaptable for high throughput and widely available. This has resulted in the utilisation of this 
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technique in determination of Mt/N in a large number of studies of clinical samples (reviewed in the 
next section). 
MtDNA quantity in the periphery, in circulating peripheral blood cells as well as in cell-free fluid of blood 
such as plasma, is a highly feasible screening tool for translational studies. However, both increases and 
decreases in MtDNA have been reported in pathogenic conditions. Currently there is no standard for 
defining what constitutes an abnormal MtDNA quantity in different sample types, and data from 
different populations for specific diseases have been inconsistent. Many methodological based issues 
can significantly alter MtDNA values (Malik et al., 2011, Malik and Czajka 2012, Chiu et al., 2003, 
Hammond et al., 2003, Kam et al., 2013). These include: 1) Duplication of the mitochondrial genome in 
the nuclear genome; 2) Use of inappropriate nuclear primers; 3) Dilution bias; 4) Template preparation 
problems. These problems can lead to serious errors and are likely to be in part responsible for the 
conflicting data in the literature. Many protocols widely used for MtDNA quantification do not meet the 
criteria of specificity and reproducibility as they fail to take into account either the co-amplification of 
nuclear regions with high identity to the mitochondrial genome, or the dilution effect (Malik et al., 
2011). Furthermore, many published papers do not give the actual copy numbers and rely instead on 
relative values, which makes the data more difficult to interpret, especially if the samples being used 
comprise of both cell free and cellular MtDNA. (For a more detailed discussion of these methodological 
issues please see Malik and Czajka 2013, Ajaz et al., 2015 and Malik et al., 2016). 
6. ACQUIRED MITOCHONDRIAL DNA CHANGES IN HUMAN DISEASES. 
The aim of this section is to highlight the growing body of evidence which when considered together, is 
strongly supports the view that MtDNA is a potentially valuable and currently largely overlooked 
biomarker for drug toxicity studies. Our focus is on studies reporting changes in MtDNA quantity under 
disease conditions rather than MtDNA damage or deletions/mutations/haplotypes. The wider 
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availability of qPCR as a methodology has led to a substantial increase in publications reporting changes 
in MtDNA content in human body fluids and tissues. Changes in MtDNA content have been described for 
a wide range of human diseases from cancer to diabetes as well as in development, ageing and exercise. 
We reviewed the literature and showed that dozens of studies had shown changes in MtDNA in a large 
number of diseases (Malik & Czajka, 2013). Since then the number of studies reporting changes in 
MtDNA in disease has risen even more sharply. 
In the cancer field, altered MtDNA levels have been observed in peripheral blood cells, saliva, tumour 
tissues, and other body fluids in numerous studies ( reviewed in Malik and Czajka 2013) leading us to 
suggest that control of MtDNA copy number may be dys-regulated in cancer.  Altered MtDNA levels 
were proposed to contribute to the risk of cancer in meta-analysis of numerous studies (Mi et al., 2015, 
Hu et al., 2016) The dys-regulation of MtDNA levels may have direct consequences for drug therapy 
response in patients. For example, in one study, the level of MtDNA in breast cancer tissue correlated 
with patient response to anthracycline chemotherapy, with higher MtDNA levels showing lower drug 
sensitivity  (Hsu et al., 2010) whereas in acute lymphoblastic lymphoma, reduced blood MtDNA after 
treatment was found to confer increased susceptibility to chemotherapy (Kwok et al., 2011).  MtDNA 
copy number changes are widely described in cancers, and interestingly it has been found that 
mitochondrial dysfunction induced by chemical depletion of MtDNA or impairment of mitochondrial 
respiratory chain in cancer cells promotes cancer progression to a chemo-resistant or invasive 
phenotype. Qu et al., (2015) found that leukocyte MtDNA was an independent prognostic marker of 
colorectal cancer and could be used to stratify patients for chemotherapy. Chen et al (2016) carried out 
a meta-analysis of 18 separate studies where MtDNA had been measured in 3961 cases from peripheral 
blood and/or tumour tissue. Their analysis suggested that increased MtDNA levels in peripheral blood 
predicted a poor cancer prognosis whereas a better outcome was presented among patients with 
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elevated MtDNA levels in tumour tissues.  Therefore, in the future, selective anticancer therapy 
development may benefit from using MtDNA alterations to inform drug design.  
In the human immunodeficiency virus (HIV) field, the impact of therapy on measureable MtDNA changes 
is very clearly indicated by evaluation in patients undergoing HIV therapy and strongly linked to the risk 
of numerous drug induced HIV complications.  Antiretroviral therapy (ART), widely used for the 
treatment of human immunodeficiency virus (HIV), can cause mitochondrial toxicity and many 
complications. Differences in MtDNA have been shown between the adipose tissue of HIV-infected and 
ART-treated subjects demonstrating that HIV therapy can impact MtDNA in organs as well as within the 
periphery showing systemic effects of drug therapy (Buffet et al., 2005). The older ART drugs such as 
nucleoside reverse transcriptase inhibitors directly affect MtDNA replication and result in tissue specific 
and organ specific pathologies, and consequently, many studies have reported MtDNA changes in 
association with drug induced complications in HIV patients. One direct mechanism of MtDNA damage is 
by the inhibition of DNA polymerase gamma, the enzyme which carries out MtDNA replication and 
which is particularly sensitive to certain antiviral drugs such as dideoxynucleoside inhibitors. As for 
various cancers, HIV treatment can cause significant changes in MtDNA and therefore it is very likely 
that control of MtDNA copy number is compromised as a consequence of HIV infection and/or 
treatment.  In-vitro experiments showed that lymphoblast cells with increased MtDNA were more 
resistant to HIV therapy (Bjerke et al., 2008) suggesting that as in cancer, altered MtDNA could have 
consequences for HIV therapy.  
Changes in MtDNA content have been described for metabolic disorders such as diabetes and obesity, 
as well as fertility, development and ageing (See Malik and Czajka 2012). We have recently shown that 
circulating MtDNA levels were independently associated with risk of diabetic nephropathy (Czajka et al., 
2015) and in a separate study circulating MtDNA levels and inflammation correlated with risk of diabetic 
retinopathy, the leading cause of adult blindness (Malik et al., 2015). The dysregulation of MtDNA 
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content in metabolic diseases suggests that changes in MtDNA content correlate with metabolic 
changes. Interestingly, the anti-diabetic drug thiazolidinedione (TZD) was shown to result in increased 
MtDNA in adipose tissue of patients with diabetes, in parallel with increased fat storage and weight gain 
(Bogacka et al., 2005). Altered MtDNA levels have also been reported in liver disease, chronic renal 
failure, haemodialysis, and in septic shock where MtDNA is believed to cause systemic inflammatory 
response syndrome (Malik & Czajka 2012). 
MtDNA changes have been reported to correlate with disease in human population based studies of 
neurodegenerative disease including multiple sclerosis (Blokhin et al., 2008, Varhaug et al., 2016), 
Parkinson’s disease (Pyle et al., 2016), Alzheimer’s disease (Lindsley et al., 2012) and Huntington’s 
disease (Peterson et al., 2014) as well as for depression (Kim et al., 2011). MtDNA has become accepted 
as an activator of both inflammation and the innate immune response, and has been shown to be the 
cause of organ injury (Oka et al.,2012). Additionally, cell free MtDNA levels in circulation were shown to 
be a high risk factor for mortality in 2 different studies of patients in intensive care units. Circulating 
MtDNA levels have been shown to be predictive of mortality in patients admitted to intensive care units 
(Nakahira et al., 2012) and also correlated with traumatic injury and sepsis (Yamamouchi et al., 2013).  
MtDNA levels have also shown to be predictive of poor outcome/death in patients who have taken drug 
overdoses (Mitchell et al., 2014).    
An interesting theme emerging from these large number of studies are the reports that suggest that 
MtDNA levels can correlate with and be an indicator of the effect of exposure to chemicals, drugs or 
environmental toxins in humans. Occupational exposure to low dose benzene can result in increases in 
circulating MtDNA  and this has been proposed to be a possible cause of increased incidence of 
leukaemia in this population (Carugno et al., 2012). Exposure to the herbicide Atrazine was shown to 
result in mitochondrial dysfunction and insulin resistance in an in-vivo study (Lim et al., 2009). Using 
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exfoliated cells from saliva, smokers were found to have increased MtDNA and this increase was 
independent of age and alcohol intake (Masayesva et al., 2006).  
Budnick et al., (2013) evaluated the impact of exposure to pesticides and found that circulating MtDNA 
showed both alterations in quantity and loss of integrity, leading the authors to propose that MtDNA 
has the potential to serve as a biomarker for recognizing vulnerable risk groups after exposure to 
toxic/carcinogenic chemicals. Even in a traditionally genetic disease with a clear nuclear mutation, 
MtDNA was proposed as a biomarker to follow the progression and treatment response of Huntington’s 
disease by Disatnik et al., (2016). In their model system, they observed both tissue and circulating levels 
of MtDNA were changing at different stages of disease and in response to treatment. 
Therefore a large body of evidence now exists showing that MtDNA levels can be measured in human 
clinical samples and that disease associated changes can be detected in populations. Indeed the 
evidence for reported alterations in MtDNA in body fluids of human patients in correlation with many 
diseases has grown rapidly and in the above section I have only been able to comment on a subset of 
these. What is clear is that there is widespread interest in using MtDNA as a biomarker in human 
populations, and with the mounting evidence for a link between patient drug response and circulating 
MtDNA levels, there is strong potential for the future use of this marker in the field of personalised 
medicine.  
7. CONCLUSIONS AND FUTURE DIRECTIONS  
Mitochondrial dysfunction is a key issue in drug development and off-target effects of many drugs may 
impact on mitochondria. Mitochondrial dysfunction contributes to drug toxicity and adverse side effects 
via many mechanisms in the cell (Mehta et al., 2008). Although structural similarities of drugs to 
electron acceptors and donors, assays based on redox dyes, and bioenergetics assays have been 
successfully employed for screens of mitochondrial effects, such assays do not easily lend themselves for 
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non-invasive use in human samples. Furthermore, there is a need to develop biomarkers for early 
detection of mitochondrial dysfunction before tissue and organ damage. Because of its early adaptive 
response to oxidative stress by increased replication and blocked transcription, MtDNA may provide an 
indicator of mitochondrial stress prior to other indicators. In addition, MtDNA lends itself to rapid 
detection via methods such as qPCR and digital PCR, making it an attractive high-throughput biomarker. 
However, methodology issues have hindered the successful use of MtDNA as a biomarker and led to 
conflicting and unreproducible findings in some cases. Of particular note in this regard is the presence of 
nuclear mitochondrial DNA segments (NUMTs) in the nuclear genome which can skew data by co-
amplifying nuclear genes when MtDNA levels are being assessed. In addition, assays currently in use 
seldom distinguish between cell free and cellular MtDNA, the former is of importance as it may be an 
indicator of inflammation, and the latter is important as it may be an indicator of bioenergetic deficit in 
the cell. Nevertheless, MtDNA copy number measurements could be successfully utilised in drug toxicity 
studies. Carefully designed assays which measure absolute copy number and take account of the 
methodological issues described above could be used in numerous stages of drug development. For 
example, initial in-vitro screens could utilise target cell lines to define if drugs in development have an 
impact on cellular MtDNA levels, and if they do, then titration studies could inform potentially safer 
levels of the drug. In-vivo animal studies could be used to study the systemic effects of potential drugs 
on MtDNA levels in organs and cells over time, and inform the potential leakage of MtDNA into the 
periphery which would have implications for inflammation. Once clinical trials commence, MtDNA levels 
in peripheral blood, compartmentalised as PMBCs for cellular and plasma for cell-free, as well as in 
urine, compartmentalised as urinary pellet for cellular debris and cell free urinary supernatant, or other 
body fluids, such as  saliva, semen, or cerebrospinal fluid, could be used to monitor the impact of the 
drug under development on systemic MtDNA levels in patients.  
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In conclusion, the growing body of evidence showing dys-regulated MtDNA levels in common diseases, 
both in cell free and cellular samples, support the view that MtDNA is a useful biomarker of 
mitochondrial dysfunction. Furthermore, emerging data from cancer, HIV and other fields indicates that 
MtDNA levels may correlate with patient response to treatment and are strongly suggestive that the 
utilisation of MtDNA as a biomarker in drug toxicity studies may be of great benefit in drug 
development.  
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Figure 3.  Changes in cellular MtDNA precede metabolic dysfunction in conditions of oxidative stress  
Growth of HMCs in high glucose led to a significant increase in cellular MtDNA which was detectable 
within 24 hours, and highly significant after 4 days (A), however the MtDNA was damaged as illustrated 
by reduced amplification of an MtDNA 8.6kb fragment (B). Cells showed normal bio-energetic profile at 
4 days (C), however after 8 days, maximal respiration and reserve capacity were significantly reduced in 
hyperglycemia cells but unaffected in normoglycmeic cells (D,E). See Czajka et al., 2015 for the full data 
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